<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>705</number>
    <updateDate>2025-11-21T18:15:45Z</updateDate>
    <updateDateIncludingText>2025-11-21T18:15:45Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2025-02-25</introducedDate>
    <congress>119</congress>
    <legislationUrl>https://www.congress.gov/bill/119th-congress/senate-bill/705</legislationUrl>
    <committees>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred To</name>
            <date>2025-02-25T16:08:58Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2025-02-25</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1347)</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2025-02-25</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>R000122</bioguideId>
        <fullName>Sen. Reed, Jack [D-RI]</fullName>
        <firstName>John</firstName>
        <lastName>Reed</lastName>
        <party>D</party>
        <state>RI</state>
        <middleName>F.</middleName>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>C001047</bioguideId>
        <fullName>Sen. Capito, Shelley Moore [R-WV]</fullName>
        <firstName>Shelley</firstName>
        <lastName>Capito</lastName>
        <party>R</party>
        <state>WV</state>
        <middleName>Moore</middleName>
        <sponsorshipDate>2025-02-25</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Cancer</name>
          <updateDate>2025-07-24T14:24:30Z</updateDate>
        </item>
        <item>
          <name>Child health</name>
          <updateDate>2025-07-24T14:24:26Z</updateDate>
        </item>
        <item>
          <name>Congressional oversight</name>
          <updateDate>2025-07-24T14:25:08Z</updateDate>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
          <updateDate>2025-07-24T14:24:54Z</updateDate>
        </item>
        <item>
          <name>Drug therapy</name>
          <updateDate>2025-07-24T14:24:50Z</updateDate>
        </item>
        <item>
          <name>Government information and archives</name>
          <updateDate>2025-07-24T14:24:59Z</updateDate>
        </item>
        <item>
          <name>Government studies and investigations</name>
          <updateDate>2025-07-24T14:25:03Z</updateDate>
        </item>
        <item>
          <name>Medical research</name>
          <updateDate>2025-07-24T14:24:40Z</updateDate>
        </item>
        <item>
          <name>Prescription drugs</name>
          <updateDate>2025-07-24T14:24:45Z</updateDate>
        </item>
        <item>
          <name>Research administration and funding</name>
          <updateDate>2025-07-24T14:24:35Z</updateDate>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
        <updateDate>2025-03-21T13:51:33Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2025-02-25</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2025-11-21T18:14:18Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;strong&gt;Innovation in Pediatric Drugs Act of 2025&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to require pediatric studies on certain orphan drugs and to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements.&lt;/p&gt;&lt;p&gt;Specifically, the bill would impose pediatric study requirements on drugs for rare diseases or conditions (i.e., orphan drugs) if the FDA determines that (1) the drug could improve the treatment, diagnosis, or prevention of a disease compared with currently available products for the relevant pediatric population; or (2) there is a need for additional options within the drug’s class or indication. (Under current law, pediatric study requirements generally do not apply to orphan drugs.) The FDA must issue guidance describing how these changes will be implemented, including information on how waivers will be granted.&amp;nbsp;&lt;/p&gt;&lt;p&gt;The bill also permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirements.&lt;/p&gt;&lt;p&gt;Additionally, the bill authorizes the National Institutes of Health to allot a certain amount of funds for priority pediatric research, including research on drugs with no remaining patents on which pediatric studies are needed.&lt;/p&gt;&lt;p&gt;Finally, the Government Accountability Office must report on the bill’s impact on rare disease drug development and on the availability of pediatric information on orphan drugs.&lt;/p&gt;</text>
        </cdata>
      </summary>
    </summaries>
    <title>Innovation in Pediatric Drugs Act of 2025</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>Innovation in Pediatric Drugs Act of 2025</title>
        <updateDate>2025-03-20T03:23:18Z</updateDate>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>Innovation in Pediatric Drugs Act of 2025</title>
        <updateDate>2025-03-20T03:23:17Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.</title>
        <updateDate>2025-03-20T03:18:22Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2025-02-25T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-119s705is/xml/BILLS-119s705is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2025-02-25</actionDate>
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1347)</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
